MeiraGTx Collaboration with Hologen AI to Expedite Phase 3 of AAV-GAD for Parkinson’s

 MeiraGTx to receive $200 million in upfront cash consideration

- MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $230 million committed capital from Hologen to fund 100% of the development of AAV-GAD for Parkinson’s disease through to commercialization, as well as other potential pipeline products

- MeiraGTx will enter into clinical and commercial supply agreements with Hologen Neuro AI Ltd to manufacture AAV-GAD and other locally delivered CNS genetic medicines

- Hologen will also fund a portion of MeiraGTx’s manufacturing operations and will own a minority stake in MeiraGTx’s manufacturing subsidiary

https://www.globenewswire.com/news-release/2025/03/13/3042086/0/en/MeiraGTx-Enters-into-a-Strategic-Collaboration-with-Hologen-AI-to-Expedite-Phase-3-Development-of-AAV-GAD-for-Parkinson-s-Disease-and-Industrialize-MeiraGTx-s-Proprietary-Manufactu.html